<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1680">
  <stage>Registered</stage>
  <submitdate>5/09/2007</submitdate>
  <approvaldate>5/09/2007</approvaldate>
  <nctid>NCT00526487</nctid>
  <trial_identification>
    <studytitle>Clinical Study to Assess Safety and Effectiveness of the Zenith® Dissection Endovascular System in Patients With Aortic Dissection</studytitle>
    <scientifictitle>Evaluation of the Safety and Effectiveness Performance of the Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissection Involving the Descending Thoracic Aorta</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>370010, TXD</secondaryid>
    <secondaryid>07-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aortic Dissection Involving the Descending Thoracic Aorta</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Zenith® Dissection Endovascular System
Treatment: devices - Endovascular Repair

Other: 1 - Endovascular Repair


Treatment: devices: Zenith® Dissection Endovascular System
The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.

Treatment: devices: Endovascular Repair
Endovascular Repair

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is survival at 30 days</outcome>
      <timepoint>30 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Measure: Clinical utility, incidence and rate of adverse events, mortality, factors related to morbidity</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Branch vessel obstruction/compromise

          -  Peri-aortic effusion/hematoma

          -  Resistant hypertension

          -  Persistent pain/symptoms

          -  Transaortic growth greater than or equal to 5 mm within 3 months (or transaortic
             diameter greater than or equal to 40 mm)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Age less than 18 years

          -  Frank rupture

          -  Diagnosed or suspected congenital degenerative connective tissue disease

          -  Systemic infection

          -  Untreatable reaction to contrast

          -  Surgical/endovascular AAA repair within 30 days

          -  Previous placement of thoracic endovascular graft

          -  Prior repair of descending thoracic aorta

          -  Interventional/open procedures within 30 days

          -  Onset of symptoms &gt; 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Device Feasibility</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>St. Vincent's Hospital Melbourne - Melbourne</hospital>
    <postcode>VIC 3065 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rostock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>William Cook Europe</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Cook Group Incorporated</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>MED Institute, Incorporated</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>William Cook Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and effectiveness performance of the
      Zenith® Dissection Endovascular System in the treatment of aortic dissections involving the
      descending thoracic aorta.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00526487</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joseph Lombardi, MD</name>
      <address>Thomas Jefferson University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>